These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21769001)

  • 1. Open trial of injectable risperidone for methamphetamine dependence.
    Meredith CW; Jaffe C; Cherrier M; Robinson JP; Malte CA; Yanasak EV; Kennedy A; Ferguson LC; Tapp AM; Saxon AJ
    J Addict Med; 2009 Jun; 3(2):55-65. PubMed ID: 21769001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label pilot study of risperidone in the treatment of methamphetamine dependence.
    Meredith CW; Jaffe C; Yanasak E; Cherrier M; Saxon AJ
    J Psychoactive Drugs; 2007 Jun; 39(2):167-72. PubMed ID: 17703711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M; Sacchetti E; Kahn JP; Medori R
    Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
    Leal A; Rosillon D; Mehnert A; Jarema M; Remington G
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):811-6. PubMed ID: 15386706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
    Lindenmayer JP; Khan A; Eerdekens M; Van Hove I; Kushner S
    Eur Neuropsychopharmacol; 2007 Jan; 17(2):138-44. PubMed ID: 17049818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
    J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.
    Rabinowitz J; Napryeyenko O; Burba B; Martinez G; Neznanov NG; Fischel T; Baylé FJ; Cavallaro R; Smeraldi E; Schreiner A
    J Clin Psychopharmacol; 2011 Feb; 31(1):75-81. PubMed ID: 21192147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
    Galloway GP; Koch M; Cello R; Smith DE
    BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
    Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
    Kissling W; Glue P; Medori R; Simpson S
    Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
    Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
    J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.